Latest ArticlesThe U.S. FDA approved 53 new drugs in 2023, including 31 chemical small molecules, 21 biological products and 1 botanical drug. According to the prescription information for professionals and the related literature as well as patent information, this review describes the descriptions, indications, mechanism of action, dosage forms and strengths, adverse reactions, and one synthetic route of the chemical small molecules, and brief information about biological and botanical products.
Hypoxia, a critical environmental characteristic of advanced solid tumors, not only stimulates the proliferation and metastasis of cancer cells, but also becomes one of the main obstacles in the process of tumor treatment. Consequently, manipulating hypoxia within tumor microenvironment is deemed an effective approach to enhance the success rate of cancer therapy. With the progressions in nanotechnology and material science, nanobiomaterial-assisted oxygen therapy has garnered increasing interest in the field of cancer treatment. This review mainly summarizes three strategies based on nanobiomaterials to alleviate tumor hypoxia according to the oxygen supplementation methods at the tumor sites, namely, the remodeling of the tumor microenvironment (endogenous oxygen supplementation), targeted delivery of nanoscaled oxygen carriers (exogenous oxygen transport), and in situ oxygen catalytic regeneration. It is hoped that this review can provide new ideas for researchers in the study of tumor hypoxia relief.
Particulate matter can indicate potential quality problems and immunogenic risks of injections, so as to be a necessary indicator for injection evaluation in the quality management. Microflow digital imaging (MDI) is a new technology for detecting particulate matter. Compared with the light obscuration method, which is the “gold standard” for particulate matter analysis, MDI can not only provide the detailed information on the size and quantity of particles, but also obtain the type and shape characteristics through high-resolution images. In addition, MDI requires a small sample volume and is especially suitable for the quality analysis of protein drug injections. From prospects of the formation causes of particulate matter and the technical requirements of drug regulatory agencies and pharmacopoeias in various countries for the quality control of particulate matter in injections, this paper reviews the application progress of MDI technology in formulation development and process research of protein drugs, in order to ensure the safety and efficacy of protein drug formulations.
Travoprost(13) was obtained with benzoyl Corey lactone(1) as the starting material in a ten-step synthetic route, which consisted of selective oxidation in the presence of 2,2,6,6-tetramethyl-1-piperidinyloxy(TEMPO)/sodium hypochlorite, Wittig-Hornor reaction, chiral reduction, debenzoylation, triethylchlorosilane protection of hydroxyl, lactone reduction, Wittig reaction, ester formation, hydroxyl protection and deprotection, with the total yield of 15.3%. The structure of the final product was confirmed by 1H NMR, 13C NMR and MS. In this paper, the separation and purification processes of various intermediates were simplified by pulping with ethanol/n-hexane, recrystallization by methyl tert-butyl ether and separation by silica gel column chromatography. By the way, the synthetic route had the advantages of availability of raw materials, and mild and controllable reaction conditions, which could provide some references for the industrial production of travoprost generic drugs.
Starting with ethyl nicotinate(4) and 3-chlorobenzyl cyanide(5) as raw materials, through the Claisen condensation, acid hydrolysis and decarboxylation, 2-(3-chlorophenyl)-1-(pyridin-3-yl)-1-ethanone(6) was obtained. Compound 3-(3-chlorophenethyl)pyridine(7) was generated by Huang Minglong reduction with hydrazine hydrate. After sodium tungstate catalysis and subsequent oxidation with hydrogen peroxide, followed by the Reissert-Henze pyridine cyanation reaction, 3-(3-chlorophenethyl)-2-cyanopyridine(8) was obtained. After hydrolysis and ring closure, 8-chloro-10,11-dihydro-4-aza-5H-dibenzo[a,d]cyclohept-5-one(3) was obtained. Then compound 3 reacted with 1-[(5-methylpyridin-3-yl)methyl]-4-piperidone(12) by McMurry coupling reaction and salted with fumaric acid, resulting in rupatadine fumarate(1). The overall yield was 28.0%(based on 4), with a purity of 99.7%. This synthetic route avoids the use of Grignard reagents. Additionally, the cyclization employs a “one-pot” method, providing convenient operation and suitability for industrial production.
An improved synthetic process of the intermediate of tofacitinib, 4-chloro-7H-pyrrolo[2,3-d]-pyrimidine(1), was described in this paper. Started from malononitrile, the desired product 1 was synthesized via α-alkylation with bromoacetaldehyde diethyl acetal(2), cyclization with thiourea, deprotection, cyclization, acidification, removal of the thiol group, as well as Sandmeyer chlorination, with an overall yield of 49%(based on 2) and a purity of 99.10%. The improved process had three apparent advantages compared with previously reported procedures, including:① direct precipitation of the potassium 4,6-diamino-5-(2,2-diethoxyethyl)pyrimidine-2-thiolate(4), from the reaction solvent ethanol as a salt with a high yield of 85%, overcoming the technical difficulties in purifying the thiol compound;② preparation of the 4-amino-7H-pyrrolo[2,3-d]pyrimidine-2-thiol(5) via a one-pot sequential three-step reaction of deprotection, cyclization, and acidification in the presence of hydrochloric acid, simplifying the process; ③ elimination toxic reagents such as phosphorus oxychloride, 2-methyl-3,3-dichloroacrylonitrile, and 2-chloroacetaldehyde, which ensured process safety and improved environmental friendliness, especially the elimination of phosphorus oxychloride. All the raw materials and reagents used in the improved syntheses are inexpensive and readily available, and the operation is simple with mild conditions and high yield, which is suitable for industrial production.
Agonistic CD40 antibodies hold great potentials in the treatment of malignant tumors, yet their efficacy and safety remain to be fully established. This research identified and humanized two high-binding and high-affinity agonistic anti-CD40 monoclonal antibodies (31A2-2 and 42D11-8) via hybridoma technique, and evaluated their pharmacodynamics through the NPG mouse xenograft model. The results revealed that the modified antibodies maintained high binding affinity after measurement, and demonstrated robust activation capacity in dendritic cell activation assays, thereby stimulated dendritic cells to release IL-12. Both antibodies exhibited significant antitumor activities in NPG mice, with tumor growth inhibition rates reaching 86.83% and 87.95% respectively. This study provided data support for the development of agonistic CD40 drugs.